Literature DB >> 21801810

Neuropeptide Y impairs insulin-stimulated translocation of glucose transporter 4 in 3T3-L1 adipocytes through the Y1 receptor.

Martin T Gericke1, Thomas Schröder, Joanna Kosacka, Marcin Nowicki, Nora Klöting, Katharina Spanel-Borowski.   

Abstract

Neuropeptide Y (NPY) is expressed in adipose tissue and is involved in adipocyte metabolism. Although NPY impacts on glucose utilization in vivo, the underlying cellular mechanism is yet to be fully elucidated. In this study we investigated the effect of NPY on the insulin-stimulated translocation of glucose transporter 4 (GLUT4) from intracellular stores to the cell surface in vitro. Using cellular fractionation and immunofluorescence we analyzed the cellular localization and content of GLUT4 in 3T3-L1 adipocytes. Additionally we investigated the effect of NPY on insulin action in adipocyte cultures by assessing the phosphorylation of Akt and [(3)H]-deoxyglucose uptake. Our data suggest that in 3T3-L1 adipocytes NPY inhibits insulin-stimulated glucose uptake in a GLUT4-dependent manner. The insulin induced translocation of GLUT4 was attenuated by the Y1 receptor agonist [Phe(7),Pro(34)] pNPY, demonstrating an essential role of the Y1 receptor in GLUT4 translocation. Additionally, we observed an NPY dose-dependent impairment of Akt phosphorylation. This study provides evidence that NPY impairs the insulin sensitivity of adipocytes and suggests that the Y1 receptor could be a potential therapeutic target for type 2 diabetes.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21801810     DOI: 10.1016/j.mce.2011.07.028

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  6 in total

1.  Aberrant expression of long noncoding RNAs in cumulus cells isolated from PCOS patients.

Authors:  Xin Huang; Cuifang Hao; Hongchu Bao; Meimei Wang; Huangguan Dai
Journal:  J Assist Reprod Genet       Date:  2015-12-09       Impact factor: 3.412

2.  Neuropeptide Y mediates glucocorticoid-induced osteoporosis and marrow adiposity in mice.

Authors:  F-S Wang; W-S Lian; W-T Weng; Y-C Sun; H-J Ke; Y-S Chen; J-Y Ko
Journal:  Osteoporos Int       Date:  2016-04-14       Impact factor: 4.507

3.  Long-Term Over-Expression of Neuropeptide Y in Hypothalamic Paraventricular Nucleus Contributes to Adipose Tissue Insulin Resistance Partly via the Y5 Receptor.

Authors:  Min Long; Jiyin Zhou; Dandan Li; Lu Zheng; Zihui Xu; Shiwen Zhou
Journal:  PLoS One       Date:  2015-05-18       Impact factor: 3.240

4.  Association of Neuropeptide-Y (NPY) and Interleukin-1beta (IL1B), Genotype-Phenotype Correlation and Plasma Lipids with Type-II Diabetes.

Authors:  Roma Patel; Mitesh Dwivedi; Mohmmad Shoab Mansuri; Naresh C Laddha; Ami Thakker; A V Ramachandran; Rasheedunnisa Begum
Journal:  PLoS One       Date:  2016-10-17       Impact factor: 3.240

Review 5.  Recent Advances in Studies on the Role of Neuroendocrine Disorders in Obstructive Sleep Apnea-Hypopnea Syndrome-Related Atherosclerosis.

Authors:  Wanda Wang; Yanli Zheng; Meimei Li; Shu Lin; Huili Lin
Journal:  Nat Sci Sleep       Date:  2021-07-27

6.  Higher Serum Neuropeptide Y Levels Are Associated with Metabolically Unhealthy Obesity in Obese Chinese Adults: A Cross-Sectional Study.

Authors:  Hao-Neng Tang; Fen Xiao; Ya-Ru Chen; Si-Qi Zhuang; Yue Guo; Hui-Xuan Wu; Hou-De Zhou
Journal:  Mediators Inflamm       Date:  2020-08-04       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.